Moderna Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

modernatx.com

Founded Year

2010

Stage

IPO | IPO

Total Raised

$1.961B

Date of IPO

12/7/2018

Market Cap

52.05B

Stock Price

130.85

About Moderna Therapeutics

Moderna Therapeutics (NASDAQ:MRNA) is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA. The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.

Moderna Therapeutics Headquarter Location

200 Technology Square

Cambridge, Massachusetts, 02139,

United States

617-714-6500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Moderna Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Moderna Therapeutics in 4 CB Insights research briefs, most recently on Apr 19, 2021.

Expert Collections containing Moderna Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Moderna Therapeutics is included in 4 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Moderna Therapeutics Patents

Moderna Therapeutics has filed 140 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Gene expression
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/11/2019

3/29/2022

Immunology, Immune system, Membrane biology, Clusters of differentiation, Biotechnology

Grant

Application Date

10/11/2019

Grant Date

3/29/2022

Title

Related Topics

Immunology, Immune system, Membrane biology, Clusters of differentiation, Biotechnology

Status

Grant

Latest Moderna Therapeutics News

This time around, Lyrica's inventor is developing his Northwestern discoveries at his own biotech

May 26, 2022

Kyle LaHucik Associate Editor Richard Silverman was left in the dark for the last five years of clinical development of the drug he discovered. The Northwestern University professor found out about the first approval of Lyrica, in the last few days of 2004, like most other people: in the newspaper. What became one of Pfizer’s top-selling meds, at $5 billion in 2017 global sales before losing patent protection in 2019, started slipping out of his hands when Northwestern licensed it out to Parke-Davis, one of two biotechs that showed interest in developing the drug in the pre-email days, when the university’s two-person tech transfer team had to ship out letters to garner industry appetite. Keep reading Endpoints with a free subscription Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Tyler Patchen News Reporter Eli Lilly is looking to expand its footprint in its home Hoosier State by making a major investment in manufacturing. The pharma is investing $2.1 billion in two new manufacturing sites at Indiana’s LEAP Lebanon Innovation and Research District in Boone County, northwest of Lilly’s headquarters in Indianapolis. The two new facilities will expand Lilly’s manufacturing network for active ingredients and new therapeutic modalities, including genetic medicines, according to a press release. Keep reading Endpoints with a free subscription Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Tyler Patchen News Reporter As the Covid-19 pandemic continues to evolve, pharma companies and manufacturers are exploring how to step up production on antivirals. Pfizer is planning to expand its Kalamazoo-area facility to increase manufacturing capabilities for the oral Covid-19 antiviral Paxlovid, according to a report from Michigan-based news site MLive. The expansion of the facility, which serves as Pfizer’s largest manufacturing location, is expected to create hundreds of “high-skilled” STEM jobs, MLive reported. No details about the project’s cost and timeline have been released, but according to MLive, Pfizer will announce the details of the expansion at some point in early June. Keep reading Endpoints with a free subscription Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Zachary Brennan Senior Editor The FDA is offering more of an explanation of the guardrails around its program that may soon allow states to import prescription drugs in some select circumstances from Canada, but only if such imports will result in significant cost reductions for consumers. While the agency has yet to sign off on any of the 5 state plans in the works so far, and PhRMA’s suit to block the Trump-era rule allowing such imports is stalled, the new Q&A guidance spells out the various restrictions that states will have to abide by, potentially signaling that a state approval is coming. Read More May 25, 2022 08:00 AM EDTUpdated 11:35 AM Kyle LaHucik Associate Editor Terremoto Biosciences goes back a long ways, in a sense, to about a dozen years ago when Principia Biopharma was founded by UCSF professor Jack Taunton. Peter Thompson initially helmed the biotech. The company helped expand covalent small molecule inhibitors beyond oncology and into autoimmune disease by targeting cystine. But that amino acid is uncommon in a lot of proteins, offering fewer drug targets than, say, lysine, which is present in most proteins of interest. So, over the years, Taunton went back to the drawing board to check out that second amino acid. Keep reading Endpoints with a free subscription Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Zachary Brennan Senior Editor RNAi therapeutics juggernaut Alnylam Pharmaceuticals made a splash in March when it sued and sought money from both Pfizer and Moderna regarding their use of Alnylam’s biodegradable lipids, which Alnylam claims have been integral to the way both companies’ mRNA-based Covid-19 vaccines work. But now, Moderna lawyers are firing back, telling the same Delaware district court that Alnylam’s claims can only proceed against the US government in the Court of Federal Claims because of the way the company’s contract is set up with the US government. The US has spent almost $10 billion on Moderna’s Covid-19 vaccine so far. Keep reading Endpoints with a free subscription Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Moderna Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Moderna Therapeutics Rank

  • When was Moderna Therapeutics founded?

    Moderna Therapeutics was founded in 2010.

  • Where is Moderna Therapeutics's headquarters?

    Moderna Therapeutics's headquarters is located at 200 Technology Square, Cambridge.

  • What is Moderna Therapeutics's latest funding round?

    Moderna Therapeutics's latest funding round is IPO.

  • How much did Moderna Therapeutics raise?

    Moderna Therapeutics raised a total of $1.961B.

  • Who are the investors of Moderna Therapeutics?

    Investors of Moderna Therapeutics include Merck & Co., Viking Global Investors, Abu Dhabi Investment Authority, Pictet Group, BB Biotech Ventures and 18 more.

  • Who are Moderna Therapeutics's competitors?

    Competitors of Moderna Therapeutics include HDT Bio and 1 more.

You May Also Like

Dicerna Pharmaceuticals Logo
Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.

H
HDT Bio

HDT Bio is a biopharmaceutical company formed to address critical unmet needs to treat cancers and infectious diseases. It is based in Seattle, Washington.

A
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Regulus Therapeutics Logo
Regulus Therapeutics

Regulus Therapeutics (NASDAQ: RGLS), a biopharmaceutical company, focuses on the discovery and development of drugs that target RNAs to treat a range of diseases in the United States. The Company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 to treat nonalcoholic steatohepatitis in patients with type 2 diabetes/pre-diabetes. The company has strategic alliance with GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases; Sanofi to discover and develop microRNA therapeutics for fibrotic diseases; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and Biogen to evaluate the use of microRNA signatures as a biomarker for human patients with various sclerosis.

Akcea Therapeutics Logo
Akcea Therapeutics

Akcea Therapeutics (NASDAQ: AKCA) is a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

Silence Therapeutics Logo
Silence Therapeutics

Silence Therapeutics (LON: SLN) focuses on the development of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.